Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?

Area of Science:

• Hepatology
• Internal Medicine
• Gastroenterology

Background:

• The term non-alcohol fatty liver disease has been updated to metabolic dysfunction associated steatototic liver disease (MASLD).
• A new entity, metabolic dysfunction and alcohol associated liver disease (Met-ALD), has been introduced.
• Met-ALD acknowledges the frequent coexistence of metabolic dysfunction and alcohol consumption, which synergistically worsen liver injury.

Purpose of the Study:

• To delve into the aspects of risk stratification, prognosis, natural history, pharmacological management, and clinical trial design for Met-ALD.
• To provide new insights into the disease and pathogenesis of liver injury in Met-ALD.
• To highlight the clinical reality and implications of Met-ALD.

Main Methods:

• Literature review and synthesis of current knowledge on Met-ALD.
• Analysis of the interaction and pathways driven by cardiometabolic risk factors and alcohol use in Met-ALD.
• Discussion of the implications for patient stratification, screening, and therapeutic strategies.

Main Results:

• MetALD is a distinct steatotic liver disease with overlapping phenotypes of MASLD and alcohol associated liver disease (ALD).
• It fills a gap in current classifications by recognizing the frequent co-occurrence of metabolic dysfunction and alcohol use.
• This recognition facilitates accurate patient stratification, improved screening for dual risk factors, and tailored therapeutic strategies.

Conclusions:

• The introduction of Met-ALD presents challenges but also significant opportunities for research and clinical practice.
• It has implications for clinical trials, epidemiologic research, and public health initiatives.
• Met-ALD promotes a more accurate understanding and management of liver injury in patients with both metabolic dysfunction and alcohol consumption.